Camidanlumab tesirine (ADCT-301), a CD25 ADC, has been investigated in a phase 1 trial (NCT02432235) in patients with CD25+ relapsed or refractory HL and NHLs. This evidence concerns the gene IL2RA and Hodgkins lymphoma.